P2RY12 and atrial fibrillation: Hence, the conclusion regarding the safety of DOAC + APT cannot be deduced from this study.[14] The PIONEER AF-PCI trial showed similar outcome trends; however, since the trial included an additional intervention, P2Y12 inhibitor, we could not pool results from this trial.[15] It assessed the efficacy and safety of DOAC and ASA along with P2Y12 inhibitor; thus, it did not reflect the outcome trends associated with the use of DOAC plus ASA only.